ABSTRACT
The former typically reflects the interaction of genetic and environmental factors, as well as the efficiency of primary healthcare services in the detection and management of Chronic kidney disease in its early stages. Deaths, on the other hand, are directly related to the technical and organizational competence of renal replacement therapy programs. Epidemiological data are also available to local health authorities, insurance agencies, and charity organizations that share in covering the expenses of renal failure management. In 2001, and for 3 years in a row, the incidence of new cases of end-stage renal disease (ESRD) in the United States has stabilized at about 330 patients pmp. This seems to represent the true incidence among the American population, after correction of many pitfalls in data collection over the previous 18 years. Males predominate in the ESRD populations reported all over the globe. This matches with the known incidence and progression profile of most chronic kidney diseases.
